TY  - JOUR
AB  - AIMS: Coronary artery disease (CAD) is a frequent comorbidity in lung transplant (LuTx) candidates. The impact of allogenic organ transplantation and the corresponding alterations in immune response on the progression of CAD remains poorly understood. In this study, we sought to analyze the effect of donor-recipient overall human leukocyte antigen (HLA) and HLA-DQ mismatch on cardiovascular outcomes following LuTx. METHODS AND RESULTS: This retrospective analysis of adult patients receiving lung transplantation at the LMU University Hospital between 2012 and 2018 included 310 patients, the majority of whom (67.4%) had undergone double lung transplantation. There were no significant differences in the incidence of the primary composite endpoint between patients with high/low HLA mismatches (22 [7.9%] vs. 4 [12.9%]; p = 0.311). Numerically higher rates of the primary endpoint, myocardial infarction, and cardiovascular death in the low HLA mismatch group can partially be explained by differences in baseline rates of CAD and coronary sclerosis. Notably, neither HLA-DQ mismatch nor the occurrence of rejection episodes or cytomegalovirus (CMV) infection was associated with the occurrence of cardiovascular events following transplantation. CONCLUSION: In this study cohort, high HLA mismatch and HLA-DQ mismatch were not associated with increased adverse cardiovascular events. Furthermore, neither transplant rejection nor CMV infection increased the risk for cardiovascular events. The high cardiovascular event rates following LuTx necessitate meticulous cardiovascular follow-up, irrespective of immunological matching.
AU  - Gade, N.*
AU  - Seifert, P.*
AU  - Gerckens, M.
AU  - Mümmler, C.
AU  - Kauke, T.*
AU  - Dick, A.*
AU  - Veit, T.*
AU  - Roden, D.*
AU  - Hoffmann, S.*
AU  - Scherzer, M.*
AU  - Höpler, J.*
AU  - Binzenhöfer, L.*
AU  - Lanz, H.*
AU  - Michel, S.*
AU  - Schneider, C.*
AU  - Irlbeck, M.*
AU  - Tomasi, R.*
AU  - Hatz, R.*
AU  - Hagl, C.*
AU  - Massberg, S.*
AU  - Milger, K.*
AU  - Behr, J.*
AU  - Lüsebrink, E.*
AU  - Kneidinger, N.*
C1  - 74137
C2  - 57336
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Association of HLA mismatch with adverse cardiovascular events following lung transplantation: A single-center study.
JO  - Clin. Transplant.
VL  - 39
IS  - 4
PB  - Wiley
PY  - 2025
SN  - 0902-0063
ER  - 

TY  - JOUR
AB  - BACKGROUND: In order to ensure eligibility for living kidney donation, donor candidates undergo a thorough medical evaluation. This process might reveal hitherto undetected medical conditions, leading to refusal of the kidney donor candidate. Detection of such conditions may, however, also have a lifesaving effect. We report on 13 years of data from our living donor transplantation program on kidney donor candidates who were diagnosed with major medical conditions during evaluation. MATERIALS AND METHODS: We performed a retrospective analysis of living kidney donor candidates who attended our transplant center between 01/2007 and 12/2019. The main focus was on newly diagnosed medical conditions that required immediate medical attention and their prognostic significance. RESULTS: Of the 436 donor candidates who were evaluated for living kidney donation at our transplant center, 192 (44%) were accepted, while 244 (56%) were excluded from donation. Interestingly, 81 (33.1%) of the ineligible donor candidates were newly diagnosed as having a medical condition that required immediate attention. While 45 (18.5%) candidates were newly diagnosed with diabetes or prediabetes, 12 (4.9%) candidates had hitherto undetected malignancies, 10 candidates (4.1%) cardiac disease, 5 (2.0%) hypertension with end-organ damage, and 4 (1.6%) suffered from kidney disease. The remaining 4 candidates (1.6%) were diagnosed with gastrointestinal diseases, and 1 candidate (0.2%) had an endocrine disorder. CONCLUSION: A comprehensive evaluation process for living kidney donation facilitates the identification of life-changing diagnoses in a significant proportion of candidates, and secures immediate medical attention. This article is protected by copyright. All rights reserved.
AU  - Mühlbacher, T.
AU  - Nadalin, S.*
AU  - Althaus, K.*
AU  - Birkenfeld, A.L.
AU  - Heyne, N.
AU  - Guthoff, M.
C1  - 66177
C2  - 53114
TI  - Living kidney donor evaluation is associated with early identification of life-changing diagnosis in potentially healthy donor candidates.
JO  - Clin. Transplant.
PY  - 2022
SN  - 0902-0063
ER  - 

TY  - JOUR
AB  - Rank A, Nieuwland R, Delker R, Pihusch V, Wilkowski R, Toth B, Kolb H-J, Pihusch R. Surveillance of megakaryocytic function by measurement of CD61-exposing microparticles in allogeneic hematopoietic stem cell recipients. Clin Transplant 2011: 25: E233-E242. © 2011 John Wiley & Sons A/S. Abstract:  Increasing evidence suggests that circulating microparticles (MP) exposing CD61 originate predominantly from megakaryocytes. Dramatic changes in megakaryocytic homeostasis are regularly observed following allogeneic hematopoietic stem cell transplantation (HSCT) and associated with transplantation-associated complications. We studied MP plasma levels prospectively in healthy subjects (n = 10) and allogeneic HSCT recipients (n = 19) twice weekly from the start of conditioning therapy up to day 30. A total of 224 measurement points were evaluated. MP were isolated, double-stained with annexin V and anti-CD61, and analyzed by flow cytometry. In uncomplicated HSCT, we found a correlation between platelet and CD61-exposing MP count, which resulted in a constant ratio of MP per platelet. The ratio was increased in patients with active hematological malignancies before transplantation and normalized during conditioning therapy. After take, the MP ratio increased, whereas infections and microangiopathic hemolytic anemia did not affect the ratio. In patients with GvHD, a decreased MP ratio was observed depending on the grade of GvHD, possibly indicating megakaryocytic damage. The MP ratio was able to discriminate between toxic, septic, and GvHD-induced hyperbilirubinemia. We first describe CD61+ MP levels during allogeneic HSCT and postulate that the MP ratio might be a useful biomarker for the surveillance of megakaryocytes during HSCT.
AU  - Rank, A.*
AU  - Nieuwland, R.*
AU  - Delker, R.*
AU  - Pihusch, V.*
AU  - Wilkowski, R.*
AU  - Toth, B.*
AU  - Kolb, H.-J.
AU  - Pihusch, R.
C1  - 6401
C2  - 28617
SP  - E233-E242
TI  - Surveillance of megakaryocytic function by measurement of CD61-exposing microparticles in allogeneic hematopoietic stem cell recipients.
JO  - Clin. Transplant.
VL  - 25
IS  - 3
PB  - Wiley-Blackwell
PY  - 2011
SN  - 0902-0063
ER  -